Rampaul Marlon, Edun Babatunde, Gaskin Monetha, Albrecht Helmut, Weissman Sharon
From the University of South Carolina-Palmetto Health Richland, Columbia, and South Carolina Department of Health and Environmental Control, Columbia.
South Med J. 2018 Jun;111(6):355-358. doi: 10.14423/SMJ.0000000000000819.
It is anticipated that early diagnosis, linkage to care, initiation of antiretroviral therapy (ART), and retention in care would lead to reduced opportunistic infections, reduction in human immunodeficiency virus-related morbidity and mortality and reduced rates of HIV transmission. This would be expected to lead to a reduction in the lifetime cost of care (LCC). This study analyzed existing data to determine to what extent early-versus-late HIV diagnosis affects LCC.
The South Carolina Department of Health and Environmental Control electronic HIV/acquired immunodeficiency syndrome reporting system data were used for this study. The first CD4 and viral load reported to the Enhanced HIV/AIDS Reporting System of the Centers for Disease Control and Prevention are considered the initial CD4 and viral load. Late HIV diagnosis was based on a CD4 count ≤200 at diagnosis. A previously validated simulation model developed by the John Snow Institute for the South Carolina Department of Health and Environmental Control was used to determine the discounted LCC. Comparisons were made between late and early HIV diagnosis.
From 2013 through 2015, 2138 individuals were diagnosed as having HIV in South Carolina; 180 individuals were excluded from further analysis because an initial CD4 count was missing. Final analysis was based on 1958 individuals. Late HIV diagnosis occurred in 509 individuals (26%). When stratified based on CD4 count at diagnosis, the discounted LCC per person in those with an initial CD4 count ≤200 was $262,374 and in those with an initial CD4 count >500 was $416,766. Those with lower CD4 counts at diagnosis had more lost quality-adjusted life-years (QALYs; 7.95 QALYs lost per person with an initial CD4 count ≤200 compared with 4.45 QALYs lost per person with an initial CD4 count >500), more lifetime HIV transmissions (1.4 per person with an initial CD4 count ≤200 compared with 0.72 per person with an initial CD4 count >500), and lower additional life expectancy (30.73 additional years with an initial CD4 count ≤200 compared with 38.08 additional years with an initial CD4 count >500).
Although individuals with lower CD4 counts at diagnosis had a lower discounted LCC, they had more lost QALYs, more lifetime HIV transmissions, and lower additional life expectancy.
预计早期诊断、与治疗机构建立联系、开始抗逆转录病毒治疗(ART)以及持续接受治疗将减少机会性感染,降低与人类免疫缺陷病毒(HIV)相关的发病率和死亡率,并降低HIV传播率。这有望降低终身护理成本(LCC)。本研究分析现有数据,以确定HIV早期诊断与晚期诊断对LCC的影响程度。
本研究使用南卡罗来纳州卫生与环境控制部的电子HIV/获得性免疫缺陷综合征报告系统数据。向疾病控制与预防中心的强化HIV/艾滋病报告系统报告的首次CD4细胞计数和病毒载量被视为初始CD4细胞计数和病毒载量。HIV晚期诊断基于诊断时CD4细胞计数≤200。使用约翰·斯诺研究所为南卡罗来纳州卫生与环境控制部开发的一个先前经验证的模拟模型来确定贴现后的LCC。对HIV晚期诊断和早期诊断进行比较。
2013年至2015年期间,南卡罗来纳州有2138人被诊断为感染HIV;180人因初始CD4细胞计数缺失而被排除在进一步分析之外。最终分析基于1958人。509人(26%)为HIV晚期诊断。根据诊断时的CD4细胞计数分层,初始CD4细胞计数≤200者每人的贴现LCC为262,374美元,初始CD4细胞计数>500者每人的贴现LCC为416,766美元。诊断时CD4细胞计数较低者的质量调整生命年损失更多(初始CD4细胞计数≤200者每人损失7.95个质量调整生命年,而初始CD4细胞计数>500者每人损失4.45个质量调整生命年),终身HIV传播更多(初始CD4细胞计数≤200者每人传播1.4次,而初始CD4细胞计数>500者每人传播0.72次),额外预期寿命更低(初始CD4细胞计数≤200者有30.73年的额外预期寿命,而初始CD4细胞计数>500者有38.08年的额外预期寿命)。
虽然诊断时CD4细胞计数较低者的贴现LCC较低,但他们的质量调整生命年损失更多,终身HIV传播更多,额外预期寿命更低。